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ARTICLE OPEN ACCESS
Long‐term follow‐up, quality of life, and survival
of patients with Lambert‐Eaton myasthenic
syndrome
Alexander F. Lipka, MD, Marion I. Boldingh, MD, PhD, Erik W. van Zwet, PhD, Marco W.J. Schreurs, PhD,
Jan B.M. Kuks, MD, PhD, Chantal M. Tallaksen, MD, PhD, Maarten J. Titulaer, MD, PhD, and







To study survival and to characterize long-term functional impairments and health-related
quality of life (HRQOL) of patients with Lambert-Eaton myasthenic syndrome (LEMS).
Methods
In this observational study, survival of patients with LEMS, separately for nontumor (NT) and
small cell lung cancer (SCLC), was compared to that of the Dutch general population and
patients with SCLC. Disease course in patients with LEMS was recorded retrospectively.
Several scales for functional impairments and health-related quality of life were assessed.
Results
We included 150 patients with LEMS. Survival was similar to that of the general population in
65 patients with NT-LEMS. Tumor survival was significantly longer in 81 patients with SCLC-
LEMS compared to patients with non-LEMS SCLC (overall median survival 17 vs 7.0 months,
p < 0.0001). At diagnosis, 39 (62%) of 63 patients with complete follow-up data were in-
dependent for activities of daily living, improving to 85% at the 1-year follow-up. The physical
HRQOL composite score (55.9) was significantly lower than in the general population (76.3, p
< 0.0001) and comparable to that of patients with myasthenia gravis (60.5). The mental
HRQOL composite score was 71.8 in patients with LEMS, comparable to that of the general
population (77.9, p = 0.19) and patients with myasthenia gravis (70.3).
Conclusions
This study shows that patients with NT-LEMS have normal survival. Patients with SCLC-
LEMS have an improved tumor survival, even after correction for tumor stage. A majority of
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Lambert-Eaton myasthenic syndrome (LEMS) is a rare auto-
immune disorder characterized by fluctuating muscle weak-
ness, loss of tendon reflexes, and autonomic dysfunction.1,2
Muscle weakness usually starts in the proximal leg muscles,1,3
which can severely limit mobility. Symptoms usually progress
over the first months and can often be controlled by symp-
tomatic and immunosuppressive treatment.4–6
After diagnosis, symptoms can vary between long-lasting re-
mission on treatment, frequent fluctuations, and permanent
disability. Distributions of symptoms and signs have been
reported in several studies.1,3,7–9 Long-term follow-up of
muscle strength scores, EMG, and voltage-gated calcium
channel (VGCC) antibody results has been reported in 47
patients.10 Functional impairments of patients with LEMS over
the disease course have been described in 12 patients only.11
Associated tumors are found in 50% to 60% of patients
with LEMS, almost invariably small cell lung cancer
(SCLC).1,3,7,12 Limited data suggest some improvement of
symptoms in patients with LEMS with SCLC (SCLC-
LEMS) after treatment of the tumor.13 Previous studies have
shown a profound improved tumor survival in SCLC-
LEMS,14–18 but no data exist on the quality of life of this
period of improved survival. Hardly any data are available
determining survival and quality of life of patients with
LEMS without associated tumors.1
In this observational study, we aimed to characterize func-
tional impairments over the disease course and the quality of
life of patients with LEMS. We studied survival of all patients
with LEMS with and without associated tumors.
Methods
Patient population
From July 1, 1998, to October 1, 2015, data from all con-
secutive Dutch patients with LEMS were collected pro-
spectively, as described before.3,19 Leiden University Medical
Center has a tertiary neuromuscular outpatient clinic and is
the nationwide referral center for LEMS in the Netherlands.
Patients were also identified through diagnosis registration
databases and neuromuscular databases in university centers
up to 2003. Afterward, we approached treating neurologists of
all Dutch patients with positive results for VGCC antibodies
(assay performed in Leiden and Rotterdam for all Dutch
hospitals). This resulted in a small number of patients added
retrospectively after a positive VGCC assay and verification of
diagnosis (n = 7). One patient with LEMS who lacked most
required data was excluded from this study.
The diagnosis of LEMS was based on characteristic clinical
features, supported by either the presence of antibodies to
VGCC or abnormal decrement and 60% increment on re-
petitive nerve stimulation.2,20 Increment testing was performed
immediately after 10 to 30 seconds of voluntary contraction.
Survival
In the survival analysis, we separated the patients with LEMS
with and without associated SCLC, excluding non-SCLC from
the analysis (n = 3), as well as 1 patient with SCLC without
a known date of tumor diagnosis. Patients with LEMS without
associated tumor were compared to the general Dutch pop-
ulation as published by the Central Statistics office of the
Netherlands, matching patients with LEMS for age and year at
LEMS diagnosis and sex21 (Statline.cbs.nl22). Survival from
diagnosis of tumors in patients with LEMS with associated
SCLC was compared to survival in all patients with SCLC in
the Netherlands from 1998 to 2012, as registered in the
Netherlands Cancer Registry Netherlands Cancer Registry
operated by Netherlands Comprehensive Cancer Organisa-
tion.23 As a secondary outcome measure, both patients with
SCLC-LEMS and controls with SCLC were compared post
hoc according to tumor stage (limited or extensive disease).
Among patients with SCLC-LEMS, patients with and those
without bulbar involvement or loss of weight within 3 months
from onset were compared to show whether these variables
predicted survival. Survival of these patients was also calculated
according to patients’ Dutch-English LEMS Tumour Associa-
tion Prediction (DELTA-P) scores.24 In patients with follow-
up data, medical events leading up to death were studied to
determine their potential relation with LEMS.
Functional impairments
Disease course in patients with LEMS was recorded retro-
spectively with a semistructured interview in all available
patients alive in 2014 to 2015 in combination with medical
records. We used the modified Rankin Scale (mRS) and
Karnofsky Performance Scale (KPS) to grade functional im-
pairment. For the mRS, a structured interview was
performed.25,26 For a limited number of patients (10 of 63),
mRS and KPS scores were collected solely from medical
records. In all of these patients, extensive follow-up data were
available to derive functional limitations.
Treatment modalities, subjective response, and devices to
assist mobility were recorded for all patients. Exacerbations
Glossary
CI = confidence interval;DELTA-P = Dutch-English LEMS Tumour Association Prediction;HRQOL = health-related quality
of life; KPS = Karnofsky Performance Scale; LEMS = Lambert-Eaton myasthenic syndrome;MCS =Mental Composite Score;
MG = myasthenia gravis;mRS = modified Rankin Scale; PCS = Physical Composite Score; SCLC = small cell lung cancer; SF-
36 = Short Form-36; VGCC = voltage-gated calcium channel.
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were recorded, as defined by a subjective decrease in strength
reported by patients supported by medical records and
exacerbations requiring emergency treatment with either IV
immunoglobulin or plasmapheresis as a more robust but less
frequent criterion. Maximum disease severity was also recor-
ded as reported by patients and supported by medical records.
Health-related quality of life
Health-related quality of life (HRQOL) was assessed with the
Short Form-36 (SF-36), a self-administered validated ques-
tionnaire that was mailed to all known living patients with
LEMS in March 2012. Nonresponders were reminded twice.
Control cohorts were a population-based cohort of 464
patients with myasthenia gravis (MG) in the Netherlands
collected at the same time27 and published normative data in
the Dutch general population.28
The SF-36 is organized into 8 domains, with a score ranging
from 0 (worst HRQOL) to 100 (best HRQOL). The 8
domains are physical functioning, role physical (role limi-
tations due to physical problems), bodily pain, general health
evaluation, vitality, social functioning, role emotional (role
limitations due to emotional problems), and mental health.
These domains produce a Physical Composite Score (PCS)
and Mental Composite Score (MCS).29
The impact of baseline demographic and disease-related factors
on both PCS and MCS quality of life was first assessed by
univariate analysis. The predictors studies were chosen on the
basis of expected baseline contributors to quality of life and
likely clinical predicting factors. They were age at onset (>50 or
<50 years), sex, partner, state of employment, presence of an
associated tumor, presence of other autoimmune disease,30
pattern of muscle weakness, medication status, and mRS score.
A second multivariate analysis was performed to determine
which of these factors independently predicted HRQOL.
Statistics
Descriptive measures were presented as mean ± SD if ap-
propriate or as median with interquartile range. Baseline
variables between patients with LEMS with and without as-
sociated lung cancer were compared by use of t tests for linear
and Fisher exact tests for categorical variables. Survival anal-
ysis was calculated with Kaplan-Meier plots and log-rank tests
for nominal variables and log-rank test for trend for ordinal
DELTA-P scores. HRQOL scores for all domains and com-
posite scores were compared between LEMS, MG, and nor-
mative data in the Dutch general population with a 1-way
between-group analysis of variance followed by post hoc
comparison with the Tukey multiple-comparison test to test
all pairwise comparisons. All individual predicting variables
for PCS and MCS were first analyzed with a t test or 1-way
analysis of variance for categorical variables and linear re-
gression for mRS scores. Variables were included in a multi-
variate model only in case of a value of p < 0.20 in the
univariate analysis.31 For missing values (2.4% of data) in this
model, a 10-fold multiple imputation was performed. After
missing data imputation, a generalized linear model was
performed to determine which of these variables in-
dependently predicted HRQOL. Bonferroni correction for
multiple comparisons was used, correcting for the number of
categories for each variable. Data analysis was performed with
SPSS version 23.0 (SPSS Institute Inc, Chicago, IL) and
GraphPad Prism 6 (GraphPad, La Jolla, CA).
Standard protocol approvals, registrations,
and patient consents
The study was approved by the Medical Ethics Committee of
the Leiden University Medical Center. All patients included
for follow-up of functional impairments and quality of life
provided written informed consent.
Data availability
The data that support the findings of this study are available
from the corresponding author on reasonable request.
Results
We included 150 patients with LEMS, of whom 85 (59%) had
an associated lung cancer (flowchart for inclusion available in
figure e-1 from Dryad, doi.org/10.5061/dryad.g0t911k).
Median time from onset to diagnosis was 18 months in
patients without and 4 months in patients with an associated
SCLC. Median time from LEMS diagnosis to detection of
associated lung cancer was 0 months. A delay beyond 2 years
was found in 2 patients (35 and 41 months). The first patient
repeatedly avoided screening, while the latter was screened in
1988 according to standards of care that are currently con-
sidered insufficient. Baseline characteristics are shown in table
1 for the total LEMS population and subgroups in whom
functional impairments and HRQOL were assessed.
Survival
In the 65 patients with LEMS without an associated tumor,
life expectancy was similar to the average life expectancy in the
Netherlands adjusted for sex, age, and year of diagnosis (log-
rank test p = 0.63, hazard ratio [log-rank test] 1.16, 95%
confidence interval [CI] 0.59–2.27, figure 1; survival per-
centages are available in table e-1 from Dryad, doi.org/10.
5061/dryad.g0t911k). In 81 patients with LEMS with an as-
sociated SCLC, tumor survival was significantly longer com-
pared to patients with SCLC without LEMS (median survival
17 vs 7.0 months, respectively, p < 0.0001). According to
tumor stage, patients with SCLC-LEMS had a longer tumor
survival both in limited (median survival 19 vs 12.1 months, p
= 0.0015) and extensive (median survival 13 vs 4.9 months, p
< 0.0001, figure 2 and table e-2 available from Dryad, doi.org/
10.5061/dryad.g0t911k) disease. Data were similar after ad-
ditional correction for sex, age, and year of tumor diagnosis
(data not shown). Early bulbar muscle involvement, loss of
weight, and DELTA-P scores did not significantly affect sur-
vival in patients with SCLC-LEMS (p = 0.41, 0.58, and 0.063,
respectively).
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Table 1 Baseline characteristics for all patients with LEMS
NT-LEMS PNS-LEMS p Value
All patients (n = 150), n (%) 65 (43) 85 (57) NA
Median age at onset (IQR; range), y 51 (41–62; 13–80) 63 (56–68; 38–77) <0.0001
Female sex, n (%) 35 (54) 34 (40) 0.064
Associated lung cancer, n (%) NA 82 SCLC (96); 3 NSCLC (4) NA
Presence of autonomic symptoms, n (%) 57/63 (90) 57/65 (88) 0.78
Presence of VGCC antibodies, n (%) 55/64 (86) 77/82 0.16
Repetitive nerve stimulation
Abnormal decrement, n (%) 63/64 (98) 73/74 (99) >0.99
Abnormal increment (>60%), n (%) 61/64 (95) 68/74 (92) 0.50
Median delay onset–diagnosis (IQR; range), mo 18 (8–39; 1–265) 4 (2–9; 1–40) <0.0001
Median delay LEMS to tumor diagnosis (IQR; range), mo NA 0 (0–1; −40 to 41) NA
Median survival (IQR; range), moa Not yet reached 17 (8–37; 1–209) <0.0001
Immunosuppression, n (%) 31/64 (48) 28/85 (33) 0.064
Chemotherapy, n (%) NA 74/84 (88.1) NA
Long-term follow-up (n = 63) NT-LEMS (n = 41) SCLC-LEMS (n = 22) p Value
Median age at onset (IQR; range), y 51 (41–60; 19–80) 65 (59–67; 50–76) <0.0001
Female sex, n (%) 23 (56) 12 (55) 1.00
Maximum mRS score, n (%)
5 2 (5) 4 (18)
4 6 (15) 9 (41)
3 16 (39) 6 (27)
2 16 (39) 3 (14)
1 1 (2) 0 (0)
Median time from onset to maximum severity (IQR; range), mo 12 (6–60; 0–444) 4 (2–10; 1–28)
Median time from diagnosis to maximum severity (IQR; range), mo −1 (−4 to 5; −253 to 354) 0 (−1 to 2; −4 to 24)
Symptomatic therapy, n (%) 40 (98) 22 (100) >0.99
Immunosuppression, n (%) 21 (51) 10 (45) 0.79
Chemotherapy, n (%) NA 17 (77) NA
Exacerbation frequency, n/patient-y (% of patients) 1/6.9 (61) 1/3.2 (41) NA
Emergency treatment frequency (IVIG/PLEX), n/patient-y (% of patients) 1/20.0 (29) 1/6.7 (23) NA
HRQOL (n = 42) NT-LEMS (n = 36) SCLC-LEMS (n = 6) p Value
Median age at onset (IQR; range), y 53 (39–62; 19–71) 56 (51–69; 49–73) 0.11
Female sex, n (%) 20/36 (56) 4/6 (67) 0.69
Mean HRQOL composite scores
PCS 56.8 51.0 0.58
MCS 71.4 74.3 0.77
Abbreviations: HRQOL = health-related quality of life; IQR = interquartile range; IVIG = intravenous immunoglobulin; MCS =Mental Component Score; mRS =
modified Rankin Scale; NSCLC = non–small cell lung cancer; NT-LEMS = Lambert-Eaton myasthenic syndrome without associated tumor; PCS = Physical
Component Score; PLEX = plasma exchange; PNS-LEMS = Lambert-Eaton myasthenic syndrome with associated lung cancer; SCLC = small cell lung cancer;
VGCC = voltage-gated calcium channels.
a Median survival for SCLC was 17 (IQR 8–37; range 1–209) months; 1 of 3 patients with NSCLC was alive at 24 months, while the other 2 died at 13 and 25
months.
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In contrast to the group-wise survival analysis, individually,
LEMS likely contributed to death in 3 VGCC-positive
patients. Two patients with SCLC-LEMS had respiratory
insufficiency due to LEMS. The first had very limited response
to aggressive treatment and died of abdominal sepsis while in
the intensive care unit. The second died as a result of sudden
respiratory deterioration just after a recent intensive care unit
stay for respiratory muscle weakness. The third patient, with
probably unrelated rectal carcinoma, experienced respiratory
insufficiency shortly before his death. He had previously been
admitted to the intensive care unit for respiratory muscle
weakness but was not analyzed again for his dyspnea in
a palliative setting. In all 3 patients, respiratory muscle
weakness was likely a relevant contributing factor, although
probably not the sole cause of death.
Functional impairments
Detailed follow-up data for functional impairments were
available for 63 patients (41 with LEMSwithout tumor and 22
with SCLC-LEMS). Median follow-up was 130 months for
patients with LEMS without and 12 months for patients with
an associated SCLC. At diagnosis, 39 of 63 patients (62%)
were independent for self-care (KPS score ≥70), improving to
85% at the 1-year follow-up (figure 3 shows overall KPS and
mRS distribution). Patients with lung cancer reported more
functional impairments at any point in the disease course
(figure 4, A and B). Maximal disease severity was reached at
a median of 1 month before diagnosis, while 30% deteriorated
beyond diagnosis. In the 32 patients with LEMSwith at least 5
years of follow-up, 27 patients (84%) had reached their worst
mRS score in or before the first year after diagnosis. Patient-
reported maximal disease severity in this group was reached in
the first 2 years in 75% of patients.
During disease course, 73% of patients used any device to
assist mobility. Fifty-two percent used a wheelchair, while
only 6% were fully wheelchair dependent at any point in
disease course. Most patients required a wheelchair for only
a limited period of time.
Symptomatic treatment consisted of 3,4-diaminopyridine in
95% of patients and pyridostigmine in 68%. Of patients
treated with 3,4-diaminopyridine and pyridostigmine, 88%
noticed a subjective improvement in symptoms due to 3,4-
diaminopyridine and 67% due to pyridostigmine. Immuno-
suppressive treatment was started in 49%, of which the most
common therapies were either prednisone combined with
azathioprine (29%) or prednisone alone (14%). The fre-
quency of both immunosuppressive and emergency treat-
ments showed no significant differences between patients
with LEMS with and without SCLC (data not shown). Pos-
itive treatment effect, as shown by an improvement in mRS
scores after diagnosis, was heterogeneous but generally
reached in 6 to 12 months (figure 4, C and D). Patients
treated with immunosuppressive drugs reported more func-
tional impairments at diagnosis compared to those treated
symptomatically but had a comparable mRS score distribu-
tion 2 and 5 years after diagnosis.
Exacerbations reported by patients occurred in 54% of
patients. These self-reported exacerbations overall occurred
once in every 5.7 patient-years. Exacerbations requiring
emergency treatment with either or plasmapheresis were less
frequent, occurring in 27% of patients, overall once in every
16 patient-years of follow-up. Nine patients with SCLC-
LEMS had follow-up data available after tumor recurrence; of
Figure 1 Survival of NT-LEMS compared to matched Dutch
life expectancy
Kaplan-Meier curve showing survival of patients with Lambert-Eaton my-
asthenic syndrome without an associated tumor (NT-LEMS) compared to
the average life expectancy in theNetherlands after adjustment for sex, age,
and year of diagnosis. Dotted thin lines represent 95% confidence interval,
and small vertical lines represent censored data for the patients with LEMS.
Figure 2 Survival of SCLC-LEMS compared to all Dutch
patients with SCLC, LD or ED
Kaplan-Meier curve showing tumor survival of patients with Lambert-Eaton
myasthenic syndromewith an associated small cell lung cancer (SCLC-LEMS)
(1998–2015) compared to the average life expectancy of patients with SCLC
in the Netherlands (1998–2012) divided according to tumor stage. Small
vertical lines represent censored data for the patients with LEMS. ED = ex-
tensive disease; LD = limited disease.
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them, only 2 had a simultaneous worsening of LEMS. One of
these patients, however, had concurrent pancreatitis, and the
other had experienced 2 previous LEMS exacerbations with-
out tumor recurrence. Five patients went into full remission
and were able to stop all treatment at a median of 4 years after
diagnosis; they remained in remission without any symptoms
or treatment on long-term follow-up (median 12 years). One
of these patients was treated for SCLC and one with immu-
nosuppressants. Two other patients were treated only
symptomatically, and the last patient with a short disease
course received no treatment at all, suggesting that even
spontaneous remission without immunomodulating therapy
is possible.
Two patients in the SCLC-LEMS group had paraneoplastic
cerebellar degeneration as a second paraneoplastic disease.
This had relevant effects on physical limitations, but these
patients ultimately had an mRS score time course comparable
to that of other patients.
Health-related quality of life
Forty-four of 67 (66%, 6 with SCLC) patients with LEMS
alive and included at the time responded to our SF-36 ques-
tionnaire. Two questionnaires were excluded due to in-
complete data. Patients with LEMS scored lower on the
physical HRQOL than the general Dutch population (PCS
55.9 [95% CI 48.9–62.9] vs 76.3 [95% CI 75.0–77.5], re-
spectively, p < 0.0001), reflected in lower scores in 3 of 4
related domains (physical functioning, role physical, general
health, figure 5; scores for all domains are available in table e-3
available from Dryad, doi.org/10.5061/dryad.g0t911k).
HRQOL scores were comparable for the MCS (71.8 [95% CI
65.4–78.3] vs 77.9 [95% CI 76.8–79.0], p = 0.19) but lower
for the vitality and social functioning domains (table e-3
available from Dryad, doi.org/10.5061/dryad.g0t911k). Be-
tween LEMS and MG, the composite scores and most of the
domain subscores were comparable except for lower scores
for patients with LEMS in the physical functioning subdomain
(45.8 vs 62.2 in MG, p = 0.0001), which is dominated by
questions involving leg strength.
Univariate analysis of potential predicting variables for phys-
ical and mental HRQOL composite scores showed employ-
ment status, pattern of muscle weakness, and mRS scores to
be significantly associated with PCS (table 1). State of em-
ployment and whether patients had a partner were associated
with MCS. A multivariate analysis aiming to detect in-
dependent predictors for quality of life (table 1) showed
having a partner and employment status to be independently
associated with higher PCS and MCS. In addition, a higher
HRQOL was linked to a more limited pattern of muscle
weakness for the PCS and male sex for the MCS. The mRS
score did not affect either PCS or MCS in this multivariate
model.
Discussion
This study shows that patients with LEMS without an asso-
ciated tumor have a normal survival, confirms that patients
with SCLC-LEMS have an improved tumor survival com-
pared to patients with SCLC without LEMS, and shows that
patients with LEMS can have a relatively well-controlled life
with mainly physical limitations and normal mental quality of
life.
In contrast to patients with MG, we show that survival in
patients with LEMS without an associated tumor was similar
to the average life expectancy in the Netherlands.32–34 The
increased mortality in MG was at least partially related to an
increase in respiratory disease as a cause of death,35 likely
related to respiratory muscle weakness, which can occur in
Figure 3 Distribution of functional impairments during the disease course
Distribution of (A) modified Rankin Scale (mRS) and (B) Karnofsky Performance Scale (KPS) scores at onset of symptoms; diagnosis; 1, 3, 6, 12, 24, 60, and 120
months after diagnosis; andmaximal (max) disease severity. At diagnosis, 62% of patientswere independent for self-care (KPS score ≥70), increasing to 68% 1
month later and 85% 1 year later. Atmaximumdisease severity, 46% of patients were independent for self-care. Number of patients available at top of bar for
each time point.
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both MG and LEMS but might be less frequent in patients
with LEMS given the lack of an increase in mortality.
Our study shows that tumor survival is increased in all patients
with SCLC-LEMS with both limited and extensive disease.
Median survival is doubled in patients with SCLC-LEMS with
extensive disease compared to patients with SCLC without
LEMS, and overall 5-year survival is increased from 4.4% to
21%. Survival in patients with SCLC without LEMS (limited
disease) is comparable to that of patients with SCLC-LEMS
with extensive disease. Several previous smaller studies have
reported this improved survival,14,15,36 including a recent pro-
spective cohort study of patients with SCLC with and without
LEMS.17 Our study shows that this improved survival cannot
merely be attributed to tumor stage (patients with SCLC-
LEMS are more frequently found while still having limited
disease). There will be an inevitable lead-time bias due to earlier
diagnosis of SCLC because of neuromuscular symptoms, but
this cannot fully explain the survival difference. This additional
improvement in survival supports a biochemical or immuno-
logic cause such as an antitumor immune response.
We show that the majority of patients with LEMS have
a relatively stable disease course after diagnosis and treatment.
Most patients either remain or become independent for self-
care over time after appropriate treatment. Because disease
severity directly affects treatment decisions, especially
whether to add immunosuppressive treatment, we could not
compare the effect of individual treatments. We did note that
patients treated symptomatically improve sooner after di-
agnosis than those treated with immunosuppressive drugs
(probably a confounder by indication), but both groups ul-
timately reach a relatively stable level of limitations ≈2 years
after diagnosis. Maximum disease severity has already been
reached before diagnosis in a majority of patients and within
the first 2 years in ≈80%, the latter of which is very similar to
that in MG.34,37 Patients with LEMS with associated lung
cancer report more functional impairments over the entire
Figure 4 Distribution of functional impairments during the disease course for subgroups
Distribution of modified Rankin Scale (mRS) scores for patients (A) with and (B) without associated lung cancer and those treated (C) purely symptomatically
and (D) with immunosuppressants as well. Data presented at onset of symptoms, diagnosis, 1 to 120 months after diagnosis, and at maximal (max) disease
severity. Number of patients available at top of bar for each time point. DAP = 3,4-diaminopyridine.
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disease course. Both LEMS symptoms, which can be more
progressive in SCLC-LEMS,3,16,24 and lung cancer and related
treatment are likely to contribute to disability in this group.
Patients with SCLC-LEMS also seem to have a higher exac-
erbation rate, although this should be interpreted with caution
because follow-up in this group is shorter and exacerbations
seem more likely to occur in the first years after diagnosis. It
should be noted, however, that most of these patients still
become independent for activities of daily life after treatment
and seem to have overall HRQOL comparable to that of
patients with LEMS without an associated tumor (table 1).
This supports the notion that low performance scores due to
muscle weakness in SCLC-LEMS should not be a reason to
refrain from tumor treatment, especially because tumor
treatment can improve symptoms in paraneoplastic disease.13
In patients with LEMS with associated lung cancer, LEMS
symptoms usually precede tumor diagnosis. However, after
initial treatment and improvement of both diseases, fre-
quently no exacerbation of LEMS occurs on tumor pro-
gression as a (repeated) warning. This could mean either that
tumor progression does not elicit such a strong immune re-
sponse as the initial tumor presentation or that an exacerba-
tion of LEMS would require more time to develop, as is the
case before the start of the disease.
The reduced HRQOL in patients with LEMS was comparable
to that in patients with MG and related mostly to physical
limitations. General demographic factors seemed to predict
variation in HRQOL that was at least as strong as disease-
specific variables in our population, especially for mental health.
Several previous studies inMG have reported reducedHRQOL
in patients withMG for most domains of the SF-36.27,38–40 Our
study showed female sex, generalized disease, and lack of em-
ployment to be associated with reduced HRQOL, comparable
to results in 2 largeMG studies.27,41 In contrast to the pattern of
muscle weakness, the mRS score as a marker for disease severity
did not independently predict HRQOL. This could be related
to the limited number of patients, limited overall variation in
mRS scores, or confounding by also including the pattern of
weakness in the model.
The largest previous study concerning disease course in LEMS
(n = 47) focused on muscle strength scores and EMG and
antibody results. In contrast, we report patient-oriented out-
comes, including functional impairments and quality of life.10
This previous study10 also reported a variable prognosis, with
sustained clinical remission in 43% of patients and about
a quarter of patients remaining (at least partially) wheelchair
dependent at follow-up. In this cohort, both treatment with
immunosuppressants and sustained clinical remission occurred
more frequently compared to our study. Although this might
suggest an association between the two, we consider it more
likely a difference in definition of clinical remission, because
many patients in our study still report a decrease in their level of
work and social activities even after substantial or apparent full
clinical improvement without major objective weakness at the
outpatient clinic. A smaller study of 12 patients with LEMS
reported lifestyle limitations comparable to our cohort, with
restrictions in activities of daily living in 75% of patients, poor
reported health status, and lowHRQOL scores as measured by
EQ-5D utility scores.11 Previous follow-up of 16 patients with
SCLC-LEMS reported sustained improvement of LEMS after
tumor treatment.13 Our study confirms that patients with
SCLC-LEMS can improve and regain independence for self-
care, but these patients still experience limitations in daily life.
Limitations of our study include a relatively small sample size
inherent to the rarity of this disease, the partly retrospective
nature of the study, and the use of different subpopulations for
Figure 5 Health-related quality of life in LEMS compared to MG and the Dutch general population
All scores range from 0 to 100. PCS = Physical
Composite Score; MCS = Mental Composite
Score; SF-36 = Short Form-36. *A significant
difference between patients with Lambert-
Eaton myasthenic syndrome (LEMS) and the
Dutch general population. **A significant dif-
ference between LEMS and myasthenia gravis
(MG).
e518 Neurology | Volume 94, Number 5 | February 4, 2020 Neurology.org/N
disease course and HRQOL. The limited number of deaths in
our study precludes a certain conclusion that survival is nor-
mal in patients with LEMS without associated tumor. Lacking
sufficient EMG or laboratory parameters for comparison, we
specifically focused on patient-oriented outcomes because
they represent patients’ limitations best. Functional impair-
ments could have been influenced by comorbidity, but this
effect is group-wise minimal in that only 2 of 22 patients with
SCLC-LEMS had another paraneoplastic neurologic disease
(cerebellar degeneration). In addition, in the few patients with
relevant comorbidity, the level of physical functioning
appeared to be determined mainly by LEMS.
This study provides detailed information on long-term
prognosis and limitations in LEMS. This can guide expect-
ations of doctors and patients and be of potential relevance for
treatment choices. Although LEMS is usually a chronic dis-
ease with long-term physical limitations and reduced quality
of life, appropriate treatment results in a relevant decrease in
functional impairments for most patients.
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